MRD Detection

TLA-based targeted sequencing provides breakpoint sequences resulting from structural changes or gene fusions.


These breakpoint sequences can be the basis for personalised qPCR-based minimal residual disease tests. 


Minimal residual disease (MRD) tests are used to determine prognosis and response to therapy in acute and chronic leukaemia, lymphoma and myeloma patients.


Cergentis supports the development of personalised MRD tests with its kits and services.  


Examples of the use of genomic breakpoint sequences in qPCR-based minimal residual disease tests by leading European diagnostic labs are presented in the application note below. 



  • "We use TLA to sequence gene fusions and other rearrangements in genes of interest. We have been impressed by the quality of TLA and Cergentis’ work and are testing the use of identified breakpoint sequences as targets for personalised minimal residual disease tests.”

                                  Princess Máxima Center for Pediatric Oncology                              

    Dr. Roland Kuiper - Senior PI (Utrecht, The Netherlands)

  • "Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”

                                                                University of Turin                                                                    

    Prof. Dr. Alfredo Brusco - Department of Medical Sciences (Italy)

  • "Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”

                                    Ghent University                                  

    Prof. Dr. Pieter van Vlierberghe - Center for Medical Genetics (Belgium)

© 2012-2019 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.